Adaptimmune Therapeutics PLC – ADR (ADAP) Impresses in Second Solid Tumor
The potential cancer-cure disclosure that propelled Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) stock up 26% today indicate innovation in cancer research and treatment that many investors say could keep Adaptimmune aloft.
Adaptimmune reported three partial responses (two confirmed and one to be confirmed), and one stable disease in the first four patients dosed with NY-ESO SPEAR T-cells in a second solid tumor: myxoid/ round cell liposarcoma (MRCLS). Patients tolerated treatment well with cytokine release syndrome (CRS) managed following standard treatment guidelines. GlaxoSmithKline exercised its option to exclusively license the right to research, develop, and commercialize NY‑ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing.
Adaptimmune CMO Rafael Amado commented, “We are encouraged by the initial responses seen in the first patients with MRCLS treated with NY-ESO SPEAR T-cells, as it validates the potential of our platform to treat a broad range of tumors, including those that are known to be unresponsive to current immunotherapies […] Although MRCLS is a soft tissue sarcoma which commonly expresses NY-ESO, there are fundamental differences in its clinical course, natural history, molecular signature, and responsiveness to standard treatments that make it distinct from synovial sarcoma. As we expect data from our other trials with our wholly owned assets throughout 2018, these results in a second solid tumor strengthen our conviction that our pipeline of unique TCRs will be capable of addressing multiple solid tumors.”
In addition to the NY-ESO program, clinical momentum continues across the company’s wholly owned programs with:
- Patients enrolling in the one billion target cell dose cohort of the MAGE-A10 triple tumor study
- Dosing in the initial safety cohort (100 million cells) of the MAGE-A4 “basket” study
Where does the Street side on this volatile biotech player? It appears mostly bullish, as TipRanks analytics demonstrate ADAP as a Buy. Out of 3 analysts polled in the last 12 months, two are bullish on Adaptimmune stock while one remains sidelined.